MiMedx Q1 sales fall 33%, miss estimates, cuts 2026 outlook

MiMedx

29/04/2026 21:15

Overview

US wound care products maker's Q1 sales fell 33% yr/yr, missing analyst expectations

Company cut 2026 net sales and adjusted EBITDA forecasts due to Medicare reimbursement changes

Wound segment sales dropped 60% on reimbursement disruption; surgical sales rose 13%

Outlook

MiMedx lowers 2026 net sales outlook to $260 mln-$290 mln

Company expects 2026 adjusted EBITDA to be approximately breakeven

MiMedx anticipates $40 mln in annualized cost savings from restructuring actions

Result Drivers

MEDICARE REIMBURSEMENT CHANGES - Co said new Medicare reimbursement policies caused significant confusion and inconsistent implementation, leading to a sharp decline in Wound segment sales

WOUND SEGMENT DECLINE - Wound business sales fell 60% yr/yr due to reimbursement disruption and slow market adjustment to new rules

SURGICAL SEGMENT GROWTH - Surgical product sales rose 13% yr/yr, led by AMNIOFIX, AMNIOEFFECT and particulate portfolio

Company press release: ID:nGNXRxfcr

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Miss
$58.99 mln
$65.02 mln (5 Analysts)
Q1 Net Income
-$10.86 mln
Q1 Gross Profit
$41.62 mln
Q1 Operating Income
-$16.05 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MiMedx Group Inc is $7.50, about 120.6% above its April 28 closing price of $3.40

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 22 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)